|
1
|
Scelo G and Larose TL: Epidemiology and risk factors for kidney cancer. J Clin Oncol. 36:JCO20187919052018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Moch H, Cubilla AL, Humphrey PA, Reuter VE and Ulbright TM: The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: Renal, penile, and testicular tumours. Eur Urol. 70:93–105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Richard S, Gardie B, Couvé S and Gad S: Von Hippel-Lindau: How a rare disease illuminates cancer biology. Semin Cancer Biol. 23:26–37. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shen C and Kaelin WG Jr: The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol. 23:18–25. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, et al: HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 14:435–446. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Meléndez-Rodríguez F, Roche O, Sanchez-Prieto R and Aragones J: Hypoxia-inducible factor 2-dependent pathways driving von Hippel-Lindau-deficient renal cancer. Front Oncol. 8:2142018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hoefflin R, Harlander S, Schäfer S, Metzger P, Kuo F, Schönenberger D, Adlesic M, Peighambari A, Seidel P, Chen CY, et al: HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice. Nat Commun. 11:41112020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Choueiri TK and Kaelin WG Jr: Targeting the HIF2-VEGF axis in renal cell carcinoma. Nat Med. 26:1519–1530. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Semenza GL: Heritable disorders of oxygen sensing. Am J Med Genet A. 185:2576–2581. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim WY and Kaelin WG: Role of VHL gene mutation in human cancer. J Clin Oncol. 22:4991–5004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, Wykoff CC, Maher ER, Harris AL, Ratcliffe PJ and Maxwell PH: HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron. Cancer Cell. 1:459–468. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, et al: Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 469:539–542. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, Leng N, Pavía-Jiménez A, Wang S, Yamasaki T, Zhrebker L, Sivanand S, Spence P, et al: BAP1 loss defines a new class of renal cell carcinoma. Nat Genet. 44:751–759. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C, Latimer C, et al: Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature. 463:360–363. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hsieh JJ, Le VH, Oyama T, Ricketts CJ, Ho TH and Cheng EH: Chromosome 3p loss-orchestrated VHL, HIF, and epigenetic deregulation in clear cell renal cell carcinoma. J Clin Oncol. 36:JCO20187925492018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Benusiglio PR, Couvé S, Gilbert-Dussardier B, Deveaux S, Le Jeune H, Da Costa M, Fromont G, Memeteau F, Yacoub M, Coupier I, et al: A germline mutation in PBRM1 predisposes to renal cell carcinoma. J Med Genet. 52:426–430. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chowdhury B, Porter EG, Stewart JC, Ferreira CR, Schipma MJ and Dykhuizen EC: PBRM1 regulates the expression of genes involved in metabolism and cell adhesion in renal clear cell carcinoma. PLoS One. 11:e01537182016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hargreaves DC and Crabtree GR: ATP-dependent chromatin remodeling: Genetics, genomics and mechanisms. Cell Res. 21:396–420. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gao W, Li W, Xiao T, Liu XS and Kaelin WG Jr: Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL −/− clear cell renal carcinoma. Proc Natl Acad Sci USA. 114:1027–1032. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Murakami A, Wang L, Kalhorn S, Schraml P, Rathmell WK, Tan AC, Nemenoff R, Stenmark K, Jiang BH, Reyland ME, et al: Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma. Oncogenesis. 6:e2872017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, et al: Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 69:4674–4681. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR, O'Brien T, Martincorena I, Tarpey P, Angelopoulos N, Yates LR, et al: Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal. Cell. 173:611–623.e17. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, Egevad L, Algaba F, Moch H, Grignon DJ, et al: The International society of urological pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 37:1490–1504. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gattolliat CH, Couvé S, Meurice G, Oréar C, Droin N, Chiquet M, Ferlicot S, Verkarre V, Vasiliu V, Molinié V, et al: Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease. Int J Oncol. 53:1455–1468. 2018.PubMed/NCBI
|
|
25
|
Messai Y, Gad S, Noman MZ, Le Teuff G, Couve S, Janji B, Kammerer SF, Rioux-Leclerc N, Hasmim M, Ferlicot S, et al: Renal cell carcinoma programmed death-ligand 1, a new direct target of hypoxia-inducible factor-2 alpha, is regulated by von hippel-lindau gene mutation status. Eur Urol. 70:623–632. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nam SJ, Lee C, Park JH and Moon KC: Decreased PBRM1 expression predicts unfavorable prognosis in patients with clear cell renal cell carcinoma. Urol Oncol. 33:340.e9–16. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jiang W, Dulaimi E, Devarajan K, Parsons T, Wang Q, Liao L, Cho EA, O'Neill R, Solomides C, Peiper SC, et al: Immunohistochemistry successfully uncovers Intratumoral heterogeneity and widespread co-losses of chromatin regulators in clear cell renal cell carcinoma. PLoS One. 11:e01645542016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gossage L, Murtaza M, Slatter AF, Lichtenstein CP, Warren A, Haynes B, Marass F, Roberts I, Shanahan SJ, Claas A, et al: Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. Genes Chromosomes Cancer. 53:38–51. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bihr S, Ohashi R, Moore AL, Rüschoff JH, Beisel C, Hermanns T, Mischo A, Corrò C, Beyer J, Beerenwinkel N, et al: Expression and mutation patterns of PBRM1, BAP1 and SETD2 mirror specific evolutionary subtypes in clear cell renal cell carcinoma. Neoplasia. 21:247–256. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Neumann HP, Bender BU, Berger DP, Laubenberger J, Schultze-Seemann W, Wetterauer U, Ferstl FJ, Herbst EW, Schwarzkopf G, Hes FJ, et al: Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma. J Urol. 160:1248–1254. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nargund AM, Pham CG, Dong Y, Wang PI, Osmangeyoglu HU, Xie Y, Aras O, Han S, Oyama T, Takeda S, et al: The SWI/SNF protein PBRM1 restrains VHL-loss-driven clear cell renal cell carcinoma. Cell Rep. 18:2893–2906. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Delahunt B, Grignon DJ and Eble JN: Tumors of the kidney. Urological Pathology. Lippincott Williams & Wilkins, a Wolters Kluwer business; Philadelphia, PA, USA: pp. 72–204. 2014
|
|
33
|
Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 366:883–892. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fisher R, Horswell S, Rowan A, Salm MP, de Bruin EC, Gulati S, McGranahan N, Stares M, Gerlinger M, Varela I, et al: Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. Genome Biol. 15:4332014. View Article : Google Scholar : PubMed/NCBI
|
